PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

	T drillood it diophays a valle Child contact Hamiles
Application Number	10/010942-Conf. #5594
Filing Date	December 6, 2001
First Named Inventor	Guriq BASI
Art Unit	1649
Examiner Name	K. A. Ballard
Attorney Docket Number	ELN-002

I EN	CLOSURES (Check all that app	14
EIA	CLOSURES (Check all that app	ועוכ
X Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for Refund	Return Receipt Postcard PTO form SB/08
X Information Disclosure Statement	CD, Number of CD(s)	Certificate of Mailing Copies of Seven (7) References
Certified Copy of Priority Document(s)	Landscape Table on CD	
Reply to Missing Parts/ Incomplete Application	Remarks	W
Reply to Missing Parts under 37 CFR 1.52 or 1.53		
/		•
SIGNATU	RE OF APPLICANT, ATTORNEY, OF	RAGENT
Firm Name LAHIVE & COCKFIE	LD, LLP	
Signature		
Printed name Debra J. Milasincio		
Date March 13, 2006	Reg. No.	46,931

					ed with the U.S. Postal Service on , Commissioner for Patents, P.O.
Box 1450, Alexandria, VA	22313-1450. /	1 1/		`	
Dated: March 13, 2006	Signature:/	1/4/	$U \setminus Z$	(Debra J. Milasincic)	•

40.								
7 57							PTO	/SB/17 (12-04
Money the Panerwork R	eduction Act of 1995	no person are rec	nuired to r	U.S. Patent	and Tradem	oved for use throug ark Office; U.S. DE	jh 7/31/2006. PARTMENT (OMB 0651-0
4			quired to t	espond to a collection		plete if Know		S CONTROL NUM
Effe Lees pursuant to the Conso	ctive on 12/08/2004 lidated Appropriatio		. 4818).	Application Nun		10/010942-Co		
FEE TR	MZNAS	ΙΤΤΔΙ		Filing Date		December 6, 2	2001	
_				First Named Inv		Gurig BASI		
Fo	r FY 200	5		Examiner Name		K. A. Ballard		-
Applicant claims s	mall entity status.	See 37 CFR 1.27		Art Unit		1649		
TOTAL AMOUNT OF P	AYMENT	(\$) 180.00		Attorney Docket	No.	ELN-002		
METHOD OF PAYM	ENT (check all t	hat apply)				_		
Check Cred	it Card N	Ioney Order	None	e Other (please ident	ify):		
X Deposit Account	Deposit Account Numb	er: 12-0080 De	posit Acco	unt Name:	Lah	ive & Cockfie	ld, LLP	
For the above-id	lentified deposit a	account, the Dir	rector is	hereby authorize	ed to: (chec	k all that apply))	
x Charge fee	e(s) indicated be	ow		Charge	e fee(s) ind	icated below, e	xcept for ti	he filing fe
	y additional fee(s		nent of	x Credit	any overpa	yments		
FEE CALCULATION		and 1.17						
1. BASIC FILING, SEAF	RCH, AND EXAM	INATION FEE	S					
		G FEES <u>Small Entity</u>	_	RCH FEES Small Entity		ATION FEES Small Entity		
Application Type	<u>Fee (\$)</u>		Fee (\$)		Fee (\$)	<u>Fee (\$)</u>	<u>Fees F</u>	Paid (\$)
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	. 0		
2. EXCESS CLAIM FEE	S					•		Small Ent
Fee Description Each claim over 20 (inc							<u>Fee (\$)</u>	<u>Fee (\$)</u>
•	- ,						50	25
Each independent claim Multiple dependent clair	•	g Keissues)					200	100
		44.					360	180
Total Claims Ex		ee (\$)	Fee Pa	aid (\$)		Iltiple Depende		
=	×	=			Fed	<u>∍ (\$)</u> <u>F</u>	Fee Paid (\$	7
Indep. Claims Ex		ee (\$)	Fee Pa	aid (\$)				_
	×	=						
If the specification and	drawings excee							
listings under 37 CF sheets or fraction th					or small en	itity) for each a	dditional 50	U
Total Sheets	Extra Sheets	Number of		ditional 50 or frac (round up to a who			<u>Fee F</u>	Paid (\$)
I. OTHER FEE(S)	\	1					Fees	Paid (\$)
Non-English Specific Other (e.g., late filing					sclosure :	Statement	18	0.00
		/					<u></u>	
SUBMITTED BY Signature	/ / 	H	Ti	Registration No.	46 024	Telephone	(617) 22	7 7400
	J. Milasincic	\sim	((Attorney/Agent)	46,931		(617) 22°	
TELLE (CITIO 1996) Debra	J. WIIIASITICIÇ	1				Date	March 13	5. ZUU6

I hereby certify that this paper (along with any paper referred to as being attached of enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to. MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 13, 2006

Signature

(Debra J. Milasincic)

March 13, 2006

Docket No.: ELN-002 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Guriq Basi et al.

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For:

HUMANIZED ANTIBODIES THAT

RECOGNIZE BETA-AMYLOID PEPTIDE

Examiner: K. A. Ballard

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2)(ii). Applicant submits herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

Application No.: 10/010942 Docket No.: ELN-002

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. ELN-002. A duplicate copy of this paper is enclosed.

Dated: March 13, 2006

DJM/JHV/mch

By____

Debra J. Milasincic Registration No.: 46,931

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant

OIPE 4033

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/010942-Conf. #5594	
11	NFORMATION	I DI	SCLOSURE	Filing Date	December 6, 2001	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Guriq BASI	
				Art Unit	1649	
	(Use as many she	eets as	necessary)	Examiner Name	K. A. Ballard	
Sheet	1	of	2	Attorney Docket Number	ELN-002	

	T		U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	702*	US-6,548,640	04-15-2003	Winter	
	703*	US-5,225,539	07-06-1993	Winter	
	704*	US-6,180,370	01-30-2001	Queen et al.	
	705*	US-5,693,761	12-02-1997	Queen et al.	
	706*	US-5,585,089	12-17-1996	Queen et al.	
	707*	US-5,859,205	01-12-1999	Adair et al.	
	708*	US-20030039645-A1	10-14-2003	Adair et al.	N.
	709*	US-6,632,927-A1	10-14-2003	Adair et al.	
	710*	US-6,407,213	06-18-2002	Carter et al.	
	711*	US-6,054,297	04-25-2000	Carter et al.	
	712*	US-6,639,055	10-28-2003	Carter et al.	
	713*	US-6,936,698-A1	08-30-2005	Taylor	
	714*	US-20050123534-A1	06-09-2005	Adair et al.	
	715*	US-20050136054-A1	06-23-2005	Adair et al.	
	716*	US-6,933,368-A1	08-23-2005	Co et al.	
	717*	US-5,648,260	07-15-1997	Winter et al.	
	718*	US-5,624,821	04-29-1997	Winter et al.	
	719*	US-6,165,745	12-26-2000	Ward et al.	
	720*	US-6,277,375	08-21-2001	Ward	
	721*	US-5,677,425	10-14-1997	Bodmer et al.	
	722*	US-5,869,046	02-09-1999	Presta et al.	
	723*	US-6,121,022	09-19-2000	Presta et al.	
	724*	US-6,194,551	02-27-2001	Idusogie et al.	
	725*	US-6,538,124	03-25-2003	Idusogie et al.	
	726*	US-6,528,624	03-04-2003	Idusogie et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	701	WO-2005/014041-A2	02-17-2005	Novartis Pharma GmbH				
	696	WO-95/06407-A1	l .	The Regents of the University of California et al				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Examiner Date Signature Considered				
Signature Considered	Examiner		Date	
	Signature		Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
				Application Number	10/010942-Conf. #5594
- IN	IFORMATIO	N DIS	CLOSURE	Filing Date	December 6, 2001
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Guriq BASI
				Art Unit	1649
	(Use as many s	sheets as n	ecessary)	Examiner Name	K. A. Ballard
Sheet	2	of	2	Attorney Docket Number	ELN-002

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	699	Clayton, David F. et al, "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," Journal of Neuroscience Research, Vol. 58:120-129 (1999)	
	698	Dictionary.com definition of, "prophylactic," pages 1-3 downloaded from internet 10/12/05	
	695	Kuo, Yu-Min et al, "Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>The Journal of Biological Chemistry</i> , Vol. 271(8):4077-4081 (1996)	
	697	Small, Gary W. et al, "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <i>PNAS</i> , Vol. 97(11):6037-6042 (2000)	
	700	Valleix, Sophie et al, "Hereditary renal amyloid osis caused by a new variant lysozyme W64R in a French Family," <i>Kidney International</i> , Vol. 61:907-912 (2002)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
DETWORK Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

cation No. (if known): 10/010942

Attorney Docket No.: ELN-002

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment **Commissioner for Patents** P.O. Box 1450. Alexandria, VA 22313-1450 /March 13, 2006 on Date Signature Debra J. Milasincic Typed or printed name of person signing Certificate 46,931 (617) 227-7400 Registration Number, if applicable Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard Transmittal (1 page)

Fee Transmittal (1 page, in duplicate)

Supplemental Information Disclosure Statement (2 pages, in duplicate)

PTO form SB/08 (32 References) (2 pages)

Copies of Seven (7) References

Charge \$180.00 to deposit account 12-0080